BMS reserves $80 million for Avalide interruption; Another recall for McNeil;

> Bristol-Myers Squibb ($BMY) has set aside $80 million to cover a possible payout to partner Sanofi ($SNY) to cover losses from a supply disruption for their jointly marketed hypertension drug Avalide. Story

> In what seems like a never-ending train of recalls, Johnson & Johnson ( $JNJ ) unit McNeil Consumer Healthcare is recalling 574,000 1-oz. bottles of grape-flavored infant Tylenol, this time because a restrictor on the cap may be pushed into the bottle and affect dosing. News

> The counterfeit versions of cancer drug Avastin discovered in the U.S. have a supply trail that includes at least Egypt, Switzerland and Britain. Item

> The EPA is looking at a $204 million plan to "cap" the Superfund site of a former American Cyanamid property in Bridgewater, NJ, that Pfizer ($PFE) got in its 2009 acquisition of Wyeth. The plan is much like the one earlier proposed by Pfizer. Story

> The European Medicines Agency said Friday that 12 of 14 drugs manufactured at the Bedford, OH, Ben Venue Laboratories plant that has been closed to address quality issues can still be prescribed. Release

> Horizon Pharma ($HZNP) says it has revised its marketing authorization application to the national procedure in the U.K. to add a recently approved Valeant Pharmaceuticals ($VRX) manufacturing plant in Laval, Quebec, as the primary site for the manufacture of Duexis (ibuprofen/famotidine). The plant previously was owned by Sanofi. Release
 

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.